deltatrials
Completed PHASE2 NCT00919295

Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome

Study of Anti-nociceptive Biogenic Amine Status, Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Thai Fibromyalgia Syndrome Patients.

Sponsor: Mahidol University

Conditions Fibromyalgia Syndrome
Interventions mirtazapine placebo
Updated 5 times since 2017 Last updated: Jul 24, 2012 Started: Dec 31, 2008 Primary completion: Oct 31, 2011 Completion: Dec 31, 2011

Listed as NCT00919295, this PHASE2 trial focuses on Fibromyalgia Syndrome and remains completed. Sponsored by Mahidol University, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mahidol University
  • University of Texas
  • University of Wuerzburg
Data source: Mahidol University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bangkoknoi, Thailand